Substituted quinolizine derivatives useful as HIV integrase inhibitors
The present invention relates to Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1 is as defined herein. The present invention also relates to compositions comprising at least one Substituted Quinolizine Derivative, and methods of using the Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject.
1. A compound having the formula (I):
wherein:
R 1 is X—C(O)—Y—R 2 ;
X is O—(C 1 -C 6 alkylene)-O or O; and
Y is a bond, O or NR 3 ;
R 2 is selected from C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl, wherein said C 1 -C 6 alkyl group can be optionally substituted with one to three groups independently selected from the group consisting of halo, hydroxy, methoxy and ethoxy;
R 3 is selected from hydrogen or C 1 -C 6 alkyl;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein X is O, or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 , wherein X is O—(C 1 -C 6 alkylene)-O, or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 , wherein Y is O, or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1 , wherein Y is a bond, or a pharmaceutically acceptable salt thereof.
6. The compound of claim 1 , wherein Y is NR 3 , or a pharmaceutically acceptable salt thereof.
7. The compound of claim 1 , wherein R 2 is selected from the group consisting of methyl; ethyl, which is optionally substituted with methoxy or ethoxy; propyl, which is optionally substituted with methoxy; or cyclopropyl; or a pharmaceutically acceptable salt thereof.
8. The compound of claim 1 , wherein R 1 is selected from:
or a pharmaceutically acceptable salt thereof.
9. The compound of claim 1 , wherein R 1 is
or a pharmaceutically acceptable salt thereof.
10. The compound of claim 1 having the structure
or a pharmaceutically acceptable salt thereof.
11. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
12. A method for the inhibition of HIV integrase in a subject in need thereof which comprises administering to the subject an effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof.
13. A method for the treatment of infection by HIV or for the treatment of AIDS or delay the onset of AIDS in a subject in need thereof, which comprises administering to the subject an effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof.
14. The composition of claim 11 , further comprising one or more additional therapeutic agents selected from raltegravir, lamivudine, abacavir, ritonavir, dolutegravir, arunavir, atazanavir, emtricitabine, tenofovir, elvitegravir, rilpivirine and lopinavir.
15. The method of claim 13 , further comprising administering to the subject one or more additional therapeutic agents selected from raltegravir, abacavir, lamivudine, ritonavir and lopinavir, wherein the amounts administered of the compound of claim 1 and the one or more additional therapeutic agents, are together effective to treat infection by HIV or to treat AIDS or delay the onset of AIDS.